Concept and structure of MeTA

812 views

Published on

Presentation on Concept and structure of MeTA by Wilbert Bannenberg, MeTA Technical Director during the MeTA Country Sharing Meeting, London, 8 December 2009.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
812
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • MeTA @ ZLC 4/12/2009 www.medicinestransparency.org
  • MeTA @ ZLC 4/12/2009 www.medicinestransparency.org
  • Title of presentation 15/01/10 MeTA
  • Title of presentation 15/01/10 MeTA
  • Title of presentation 15/01/10 MeTA
  • Title of presentation 15/01/10 MeTA
  • Title of presentation 15/01/10 MeTA
  • MeTA @ ZLC 4/12/2009 www.medicinestransparency.org
  • 4/12/2009 www.medicinestransparency.org MeTA @ ZLC
  • Concept and structure of MeTA

    1. 1. Wilbert Bannenberg Technical Director Concept and Structure of MeTA 21/7/2009
    2. 2. XXX
    3. 3. What is MeTA? <ul><li>A global alliance between: </li></ul><ul><ul><li>DFID, World Bank, WHO, private sector, civil society, professional organisations. </li></ul></ul><ul><li>Multi-stakeholder collaboration </li></ul><ul><ul><li>Government, CSOs and Private Sector </li></ul></ul><ul><li>Working in 7 pilot countries to improve access to medicines. </li></ul><ul><li>An International Secretariat to support country work, and, upon request, technical assistance. </li></ul>4/12/2009 MeTA
    4. 4. MeTA hypothesis? <ul><li>Cooperation and commitment by the 3 main stakeholder groups to disclose and jointly analyse data around the medicines supply chain will lead to better access to essential medicines </li></ul>4/12/2009 MeTA
    5. 5. Transparency? <ul><li>Improving information access, scrutiny and use, in order to support the development of viable, efficient medicines markets and supply systems that benefit all developing country consumers </li></ul><ul><ul><li>Transparency = not only disclosure of the price, quality, use, availability of medicines; but also: </li></ul></ul><ul><ul><li>how to use the information to identify barriers, and to agree on solutions </li></ul></ul>23/06/2009 MeTA
    6. 6. Key data collected in MeTA <ul><li>[Mainly through disclosures by stakeholders] </li></ul><ul><li>Price data of medicines </li></ul><ul><ul><li>Procurement prices (~ MSH Intl price indicator) </li></ul></ul><ul><ul><li>Retail prices private, public sector (~WHO/HAI methodology) </li></ul></ul><ul><ul><li>Components (tax, VAT, margins, profit etc) </li></ul></ul><ul><li>Quality and registration status </li></ul><ul><ul><li>Medicines, GMP plants, GDP wholesalers, Licensed outlets </li></ul></ul><ul><li>Availability (basket) </li></ul><ul><li>Promotion (being developed) </li></ul>23/06/2009 MeTA <ul><li>… for each area: </li></ul><ul><li>Policy </li></ul><ul><li>Practices </li></ul><ul><li>Outcomes? </li></ul>
    7. 7. Contextual information collected <ul><li>[From surveys rather than from disclosures] </li></ul><ul><li>Supply chain operations </li></ul><ul><ul><li>Supply chain mapping data </li></ul></ul><ul><li>Affordability </li></ul><ul><ul><li>Generic utilization data, cost of treatment (related to salary) </li></ul></ul><ul><li>Equitable access </li></ul><ul><ul><li>Data on health and medicines expenditure by income group, and experiences of treating key illnesses by income group. </li></ul></ul><ul><li>Rational use </li></ul><ul><ul><li>Household survey data, prescribing data in health facilities </li></ul></ul>23/06/2009 MeTA
    8. 8. Who should disclose what? <ul><li>Government : VAT, taxes, budget, selection, quantification, </li></ul><ul><li>Procurement agency : purchase & selling prices </li></ul><ul><li>DRA : quality and registration data, inspection, QC lab results </li></ul><ul><li>Private sector : prices, margins, availability, promotion codes of conduct </li></ul><ul><li>Civil society / academics : Availability (equity), Affordability, Rational use </li></ul>23/06/2009 MeTA
    9. 9. What should this lead to? <ul><li>Better information to the sector & general public </li></ul><ul><li>More engagement in MeTA Councils </li></ul><ul><li>All stakeholders better informed </li></ul><ul><li>More trust and collaboration between stakeholders </li></ul><ul><li>Seeking improved, joint solutions </li></ul><ul><li>Better access to medicines </li></ul><ul><ul><li>Key hypothesis to be proven! </li></ul></ul>23/06/2009 MeTA
    10. 10. 1. Responsibility for access <ul><li>Governments are responsible for providing access to health care, including access to essential medicines </li></ul>05/09/2009 3 MeTA FIP
    11. 11. 2. Role of transparency <ul><li>Stronger and more transparent systems and improved supply chain management will increase access </li></ul>05/09/2009 3 MeTA FIP
    12. 12. 3. Equity <ul><li>Increasing equitable access to medicines improves health and enables other human development objectives to be achieved </li></ul>05/09/2009 4 MeTA FIP
    13. 13. 4. Evidence-based policy <ul><li>Improved information about medicines can inform public debate, and provide a basis for better policy </li></ul>05/09/2009 6 MeTA FIP 2. Affordable prices ACCESS 1. Rational selection 4. Reliable health and supply systems 3. Sustainable financing
    14. 14. 5. Mutual accountability through mutli-stakeholder action <ul><li>A multi-stakeholder approach that involves all sectors – private, public and civil society - will lead to greater accountability </li></ul>05/09/2009 7 MeTA FIP
    15. 15. XXXX 21/7/2009
    16. 16. MeTA Structure <ul><li>Pilot Country National Stakeholder Forums, each with a Secretariat, </li></ul><ul><li>The International Secretariat </li></ul><ul><li>A Management Board (consisting of UK's DFID , which chairs the Board, the World Health Organization and the World Bank ) </li></ul><ul><li>An International Advisory Group </li></ul><ul><li>DFID, WHO, WB, Private Sector, Academia, Pilot Country reps </li></ul><ul><li>. </li></ul>
    17. 17. MeTA Core Principles <ul><li>Governments are responsible for providing access to health care, including access to essential medicines </li></ul><ul><li>Stronger and more transparent systems and improved supply chain management will increase access </li></ul><ul><li>increasing equitable access to medicines improves health and enables other human development objectives to be achieved </li></ul><ul><li>Improved information about medicines can inform public debate, and provide a basis for better policy </li></ul><ul><li>A multi-stakeholder approach that involves all sectors – private, public and civil society - will lead to greater accountability </li></ul>
    18. 18. MeTA’s goal <ul><li>MeTA’s overall goal is to increase access to essential medicines for the poorest of the poor in developing countries </li></ul>
    19. 19. XX
    20. 20. MeTA hypothesis? <ul><li>Cooperation and commitment by the 3 main stakeholder groups to disclose and jointly analyse data around the medicines supply chain will lead to better access to essential medicines </li></ul>4/12/2009 MeTA
    21. 21. The MeTA Pilot Disclosure of data and scrutiny by multi - stakeholder group Development of policy options Policy change and implementation Improved information for management Improved processes . New validated data on pharmaceutical sector New validated data on pharmaceutical sector Disclosure of data and scrutiny by multi - stakeholder group Development of policy options Policy change and implementation Changes in drug prices, availability, quality and/or promotion Changes in drug prices, availability, quality and/or promotion Improved information for management Improved processes . Pilot New validated data on pharmaceutical sector Changes in drug prices, availability, quality and/or promotion ££, toolkit & technical support Policy research, shared learning Sector plans, domestic and CPs

    ×